[DOI] [PubMed] [Google Scholar] 33.Yusta B., Baggio L.L., Estall J.L., Koehler J.A., Holland D.P., Li H., Pipeleers D., Ling Z., Drucker D.J
Abbasinejad, MD , for personalized tirzepatide weight loss plans at Cape Fear Physical Medicine and Rehab in Fayetteville means benefiting from her extensive expertise in Obesity Medicine
Targeted PubMed searches yielded 14 high-quality references, including clinical trials and mechanistic studies, supplemented by 4 authoritative sources due to the niche nature of recent systematic reviews on copper peptide GHK-Cu
GLP-1/GIP assets primarily target obesity and type 2 diabetes indications, but are additionally in the late-stage pipeline for a broad scope of indications including chronic heart failure, osteoarthritis and liver fibrosis